Asher Biotherapeutics, Inc.

Venture capital investment in biopharmaceutical companies ticked higher in the first quarter of 2024. In the second quarter, money is flowing into VC investors and funds focused specifically on the li

One of the leading contenders to improve on interleukin-2 (IL-2)-based therapy in oncology is down and possibly out as Nektar Therapeutics and Bristol Myers Squibb Company announced the failure of

Asher Biotherapeutics, Inc. aims to get around the problem of pleiotropy – engagement of a target across a variety of cells in the body, causing unintended side effects – by developing cell-targeted

Biopharmaceutical companies raised $1.5bn in 11 venture capital mega-rounds of $100m or more during the last week and a half of March. Including VC and other financings under $100m, 35 privately held